​​​​

Skip Navigation LinksNews

IMGN_News_Photo_3.jpg 

Press Releases

May 2, 2017

ImmunGene Regains Antibody-Interferon Fusion Product Candidates from Valor Biotherapeutics


January 8, 2016

Valor Biotherapeutics Announces First Patient Treated in Phase 1 Study of IGN002​


Augu​st 6, 2015

Valor Biotherapeutics to Begin Phase 1 Clinical Study of Novel Lymphoma Therapy​


November 7, 2013

ImmunGene Raises $9 Million in Series A Financing


June 3, 2013

​​ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein


May 22, 2013

The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients


​November 13, 2012

Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers ​

February 11, 2011

ImmunGene's Interferon Payload Technology Platform Featured in BioCentury Magazine ​

January 5, 2011

ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology ​


 

November 23, 2010

ImmunGene Receives $244,479 Grant Under The Patient Protection And Affordable Care Program For Its Anti-Cancer Technology


November 11, 2010

ImmunGene's Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today


Publications


Targeting IFN-alpha to B Cell Lymphoma cells by a Tumor-Specific Antibody Elicits Potent Antitumor Activities 
By Tzu-Hsuan Huang, Koteswara R. Chintalacharuvu, and Sherie L. Morrison 
The Journal of Immunology, 2007, 179: 6881– 6888
Tzu-Hsuan, etal.pdf


Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. 
By Xuan C, Steward KK, Timmerman JM, Morrison SL. 
Blood. 2010 Apr 8;115(14):2864-71​

Xuan, etal..pdf


Tumor antigen-specific monoclonal antibody-based immunotherapy, cancer initiating cells and disease recurrence. 
By Yangyang W., Francesco S., Ling Y., Elvira F., Xinhui W., Matteo L., Soldano F., Joseph S., and Cristina F.
B. Bonavida (ed.), Resistance to Immunotherapeutic Antibodies in Cancer

Yangyang Wang, etal....pdf


Targeting cancer initiating cells in pancreatic cancer. 
By Matteo L., Francesco S., Yangyang W., Elvira F., Ling Y., Soldano F., Xinhui W., Keith L., and Cristina F.
Matteo Ligorio, etal....pdf